MK-677 (Ibutamoren)
Growth hormone axis (non-peptide) · By Preptide Pro editorial team · Last updated
MK-677 (Ibutamoren) is a growth hormone axis (non-peptide) peptide, and it is not FDA-approved. An orally active small-molecule ghrelin-receptor agonist, not a peptide. It has been studied in clinical trials and is not approved.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 178024 |
|---|---|
| CAS number | 159634-47-6 |
| Molecular formula | C27H36N4O5S |
| Molecular weight | 528.7 g/mol |
| Other names | Ibutamoren, ibutamoreno, L 163191, L-163,191, ibutamorenum, RefChem:55388, DTXCID0089191, Ibutamoren [INN] |
Is MK-677 (Ibutamoren) FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on MK-677 (Ibutamoren)?
PubMed lists 139 records for “ibutamoren OR MK-677”, of which 19 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. | Sex Med Rev | 2026 Sep 30 |
| Peptide Supplements and Their Therapeutic Applications in Sports Medicine. | Am J Sports Med | 2026 Aug 11 |
| Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. | Analyst | 2026 Jul 27 |
| Striosomal ghrelin receptor activity controls reward-cost integration. | Res Sq | 2026 Jun 25 |
| Spontaneous Splenic Rupture in a Patient With Recent Use of Performance-Enhancing Compounds: A Case Report and Literature Review. | Cureus | 2026 Mar |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.